VCEL — Vericel Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 887359 ·
Last close
$34.97
Market Cap
$1.79B
52W High
$40.85
52W Low
$28.95
ADV30
624,690
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 68,425,000 | 49,266,000 | -8,064,000 | -6,302,000 | 485,627,000 | 109,295,000 | 129,396,000 |
| Dec 2025 | 92,918,000 | 73,128,000 | 22,415,000 | 23,243,000 | 487,969,000 | 100,092,000 | 133,329,000 |
| Sep 2025 | 67,503,000 | 49,585,000 | 3,450,000 | 5,074,000 | 453,274,000 | 100,403,000 | 131,416,000 |
| Jun 2025 | 63,240,000 | 46,613,000 | -2,029,000 | -553,000 | 435,608,000 | 80,532,000 | 128,799,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$51,910,000
Investing CF
$-43,937,000
Financing CF
$7,070,000
CapEx
$-27,162,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.31
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-376,297,000
Inventory
$17,560,000
Receivables
$84,634,000
ST Investments
$37,407,000
EBIT TTM
$18,007,000
Pretax Income TTM
$17,377,000
Interest Exp TTM
$630,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$292,086,016
EBITDA
$27,897,000
Free Cash Flow
$42,369,376
Enterprise Value
$1,723,301,504
Total Cash
$145,340,000
Total Debt
$95,042,000
Shares Out
51,068,228
Trailing EPS
$0.43
Book Value
$6.98
ROE
6.6%
ROA
2.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 276,259,000 | 11,044,000 | 16,518,000 | 487,969,000 | 133,329,000 | — | 51,910,000 |
| Dec 2024 | 237,224,000 | 4,519,000 | 10,362,000 | 432,722,000 | 140,755,000 | — | 58,163,000 |
| Dec 2023 | 197,516,000 | -6,464,000 | -3,182,000 | 353,657,000 | 127,705,000 | — | 35,311,000 |
| Dec 2022 | 164,365,000 | -17,058,000 | -16,709,000 | 273,003,000 | 80,731,000 | — | 17,687,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.85
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $34.97 · call volume: 15 · put volume: 9
Expected Move to 2026-07-17:
±$6.70
(19.16%) —
implied range
$28.27 –
$41.67
· ATM straddle on $35.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $1.83B | $4.10 | — |
| NVAX | NOVAVAX INC | $1.72B | $10.46 | — |
| ADMA | ADMA BIOLOGICS, INC. | $1.89B | $8.15 | — |
| MESO | MESOBLAST LTD | $1.93B | $14.90 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.62B | $19.20 | — |
News headlines (Yahoo Finance, 1h cache)
Analysts Have Made A Financial Statement On Vericel Corporation's (NASDAQ:VCEL) First-Quarter Report
2026-05-09 12:28 · Yahoo
Vericel Q1 Earnings Call Highlights
2026-05-09 06:07 · Yahoo
Vericel (VCEL) Q1 2026 Earnings Transcript
2026-05-08 16:31 · Yahoo
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 15:15 · Yahoo
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
2026-05-07 11:45 · Yahoo
Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet
2026-05-04 13:55 · Yahoo
Vericel Annual Meeting: Shareholders Elect Seven Directors, Approve Say-on-Pay and PwC Auditor
2026-05-01 06:05 · Yahoo
Exploring Three High Growth Tech Stocks In The US Market
2026-04-29 11:38 · Yahoo
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
2026-04-23 12:30 · Yahoo
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
2026-04-02 19:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.